Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas

References (7)

1. Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence Based Care. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma 2006;47:967-77
2. Justice TE, Martenson JA, Wiseman GA, Witzig TE. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer 2006;107:433-8
3. Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma 2003;44 (Suppl 4):S37-47
4. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B Cell non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 2005;20:185-8
5. Cilley J, Winter JN. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 2006;91:113-20
6. Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin’s lymphoma. Drugs Today 2004;40:111
7. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999;17:3793-803.